Lung cancer is the second-most common cancer and the leading cause of cancer death in the United States. Over 80% of lung ...

Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets TRBC2-positive T-cell cancers, expanding a precision approach they established ...

A hidden “jack-in-the-box” mechanism inside T cells may hold the key to unlocking more powerful cancer immunotherapies.

A study by the Mildred Scheel Early Career Center group led by Dr. Mohamed Elgendy at the TUD Faculty of Medicine provides ...

A large, multi-institution study led by a Brown University physician-scientist could have important implications for the development of new classes of cancer therapeutics.

A team at RMIT University in Melbourne say that extremely small metal particles – which they dub ‘nanodots’ – could be ...

Despite the development of numerous cancer treatment technologies, the common goal of current cancer therapies is to eliminate cancer cells. This approach, however, faces fundamental limitations, ...

Creating physiologically relevant conditions for cells that replicate in vivo environments can improve experimental results, ...

Gastric (stomach) cancer remains one of the most common and deadly cancers in East Asia, including Korea. Yet despite its ...

California biotech company Cellipont has opened a new 76,000 square foot cell therapy headquarters in The Woodlands' booming ...

Seals give birth only when conditions are right. After mating, a female seal can delay implantation of the embryo in the ...

Researchers at the Johns Hopkins Kimmel Cancer Center’s Ludwig Center developed a new treatment that selectively targets ...